Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | 10% owner | November 15, 2017 | November 16, 2017 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | 10% owner | May 24, 2021 | May 26, 2021 |
| MACROGENICS INCMGNX · Entity 6104 | 10% owner | October 02, 2023 | October 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cidara Therapeutics, Inc.
Report date November 15, 2017 · Filed November 16, 2017
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,295,272 |
Reported balance
After 2017-11-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-15 · Purchase · Acquired 60,000 · Balance 2,295,272 |
Esperion Therapeutics, Inc.
Report date May 24, 2021 · Filed May 26, 2021
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,477,964 |
Reported balance
After 2021-05-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-24 · Purchase · Acquired 100,000 · Balance 4,477,964 |
MACROGENICS INC
Report date October 02, 2023 · Filed October 04, 2023
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,929,963 |
Reported balance
After 2023-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-02 · Purchase · Acquired 150,000 · Balance 9,929,963 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Molecular Templates, Inc.
Report date November 14, 2024 · Filed November 19, 2024
Jointly reported with BB BIOTECH AG
Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-14 · Sale · Disposed 1,279,820 · Balance 0 |
| Prefunded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 134,667 |
Reported balance
After 2024-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-02 · Purchase · Acquired 134,667 · Balance 134,667 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
| Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2029-04-02 | Direct | 769,334 |
Reported balance
After 2024-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-02 · Purchase · Acquired 769,334 · Balance 769,334 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 30, 2022
Jointly reported with BB BIOTECH AG
Section 16 reporting ended · disclosed 2022-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-11 · Other · Disposed 8,733,538 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | SaleCommon Stock | 1,279,820 | $0.66 | $845,833.04 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Warrants (right to buy) · Derivative | 769,334 | $0.13 Strike: $2.35 | $96,166.75 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · derivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,334 Underlying: Common Stock · 769,334 shares Expires not disclosed F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchasePrefunded Warrants (right to buy) · Derivative | 134,667 | $2.35 Strike: $0.00 | $316,332.78 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · derivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,667 Underlying: Common Stock · 134,667 shares Expires 2029-04-02 F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 250,000 | $2.35 | $587,500.00 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,820 Read SEC document |
| April 02, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Warrants (right to buy) · Derivative | 769,334 | $0.13 Strike: $2.35 | $96,166.75 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · derivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,334 Underlying: Common Stock · 769,334 shares Expires 2029-04-02 F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchasePrefunded Warrants (right to buy) · Derivative | 134,667 | $2.35 Strike: $0.00 | $316,332.78 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · derivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,667 Underlying: Common Stock · 134,667 shares Expires not disclosed F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 19:31 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 150,000 | $4.46 | $669,585.00 |
DisclosureSEC source: 0000899243-23-019881 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,929,963 Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 19:39 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.26 | $1,052,840.00 |
DisclosureSEC source: 0000899243-23-018688 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,779,963 Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 19:14 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 4,255,319 | $0.47 | $1,999,999.93 |
DisclosureSEC source: 0000950170-23-033494 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,447,322 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:37 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 500,000 | $5.07 | $2,532,600.00 |
DisclosureSEC source: 0000899243-23-005209 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,579,963 Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:21 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 150,000 | $5.30 | $794,925.00 |
DisclosureSEC source: 0000899243-23-002378 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,079,963 Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 16:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.61 | $1,121,800.00 |
DisclosureSEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,929,963 Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 16:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.88 | $1,176,800.00 |
DisclosureSEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,729,963 Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 16:37 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 300,000 | $5.96 | $1,788,180.00 |
DisclosureSEC source: 0000899243-22-036996 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,529,963 Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 250,000 | $4.36 | $1,090,500.00 |
DisclosureSEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,229,963 Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 250,000 | $4.63 | $1,157,100.00 |
DisclosureSEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,979,963 Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 19:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 285,977 | $4.00 | $1,143,564.83 |
DisclosureSEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,729,963 Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 19:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 168,422 | $3.70 | $623,919.30 |
DisclosureSEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,443,986 Read SEC document |
| August 11, 2022 Filed Aug 30, 2022 16:05 UTC | Radius Health, Inc. RDUS · Entity 124173 | OtherCommon Stock | 8,733,538 | $10.00 | $87,335,380.00 |
DisclosureSEC source: 0000899243-22-030031 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. Read SEC document |
| May 18, 2022 Filed May 20, 2022 15:35 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 477,824 | $5.57 | $2,661,001.86 |
DisclosureSEC source: 0000899243-22-018984 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,733,538 Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:21 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 200,000 | $1.18 | $236,200.00 |
DisclosureSEC source: 0000899243-22-018544 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,192,003 Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 16:33 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 300,000 | $6.31 | $1,894,410.00 |
DisclosureSEC source: 0000899243-22-001316 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,255,714 Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 16:49 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 200,000 | $4.04 | $807,180.00 |
DisclosureSEC source: 0000899243-22-001433 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,992,003 Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:33 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 250,000 | $6.30 | $1,574,650.00 |
DisclosureSEC source: 0000899243-22-001316 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955,714 Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 17:29 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $18.50 | $3,700,320.00 |
DisclosureSEC source: 0000899243-21-045703 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,275,564 Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 19:09 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 100,000 | $20.47 | $2,047,460.00 |
DisclosureSEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,075,564 Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 14:34 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 100,000 | $12.95 | $1,294,500.00 |
DisclosureSEC source: 0000899243-21-038590 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,705,714 Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 19:09 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 100,000 | $20.64 | $2,063,960.00 |
DisclosureSEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975,564 Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 15:58 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 150,000 | $12.28 | $1,841,280.00 |
DisclosureSEC source: 0000899243-21-037557 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,605,714 Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 15:50 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 750,000 | $6.00 | $4,500,000.00 |
DisclosureSEC source: 0000899243-21-037292 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,792,003 Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 16:21 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $19.93 | $3,986,680.00 |
DisclosureSEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875,564 Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 16:21 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 400,000 | $20.94 | $8,376,800.00 |
DisclosureSEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,675,564 Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 16:17 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 100,000 | $6.13 | $613,000.00 |
DisclosureSEC source: 0000899243-21-036541 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042,003 Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 16:23 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 75,000 | $7.09 | $531,840.00 |
DisclosureSEC source: 0000899243-21-030317 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,942,003 Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:23 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $7.00 | $559,816.00 |
DisclosureSEC source: 0000899243-21-030317 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,867,003 Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 18:02 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 125,000 | $7.13 | $891,675.00 |
DisclosureSEC source: 0000899243-21-029181 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,787,003 Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 18:02 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 119,382 | $6.96 | $830,827.09 |
DisclosureSEC source: 0000899243-21-029181 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,662,003 Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 17:33 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 75,000 | $21.74 | $1,630,170.00 |
DisclosureSEC source: 0000899243-21-025485 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,275,564 Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:54 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 100,000 | $21.04 | $2,104,390.00 |
DisclosureSEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200,564 Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 18:54 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 75,000 | $20.53 | $1,539,615.00 |
DisclosureSEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100,564 Read SEC document |
| May 24, 2021 Filed May 26, 2021 15:53 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 100,000 | $20.22 | $2,021,620.00 |
DisclosureSEC source: 0000899243-21-020706 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,477,964 Read SEC document |
| May 19, 2021 Filed May 21, 2021 18:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 200,000 | $20.37 | $4,073,960.00 |
DisclosureSEC source: 0000899243-21-020330 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377,964 Read SEC document |
| May 06, 2021 Filed May 7, 2021 19:23 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 80,000 | $20.57 | $1,645,632.00 |
DisclosureSEC source: 0000899243-21-018635 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,177,964 Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:23 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 150,000 | $20.02 | $3,002,850.00 |
DisclosureSEC source: 0000899243-21-018635 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,097,964 Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 15:22 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 40,852 | $8.08 | $329,941.18 |
DisclosureSEC source: 0000899243-21-016530 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,542,621 Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 17:14 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 150,000 | $8.62 | $1,292,655.00 |
DisclosureSEC source: 0000899243-21-016175 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,501,769 Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 16:26 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 150,000 | $8.37 | $1,256,040.00 |
DisclosureSEC source: 0000899243-21-015925 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,351,769 Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 16:26 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 100,000 | $7.81 | $780,970.00 |
DisclosureSEC source: 0000899243-21-015925 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,201,769 Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 19:51 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 50,000 | $8.02 | $400,830.00 |
DisclosureSEC source: 0000899243-21-015608 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,101,769 Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 19:51 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 235,664 | $8.23 | $1,939,632.55 |
DisclosureSEC source: 0000899243-21-015608 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,051,769 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.